Sema4 announced the completion of its business combination with CM Life Sciences, a special purpose acquisition company (SPAC) sponsored by affiliates of Casdin Capital, LLC and Corvex Management LP. The resulting combined company, Sema4 Holdings Corp. (“Sema4”), will commence trading of its shares of common stock and warrants on the Nasdaq Global Select Market under the ticker symbols "SMFR" and “SMFRW” on July 23, 2021.

The merger was approved by the stockholders of CM Life Sciences on July 21, 2021. Eric Schadt, Ph.D., Founder and Chief Executive Officer of Sema4, and Sema4's current executive team will continue to lead the combined company. Sema4 intends to use the influx of capital – approximately $500 million in cash proceeds – to support its organic operating needs and capitalize on inorganic opportunities to accelerate growth through the acquisition of complementary businesses.